Experimental Hematology and Oncology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Age-related accumulation of B-1 cell progenitors in mice reflects changes in miR15a/16-1 expression and radioresistance capacity
AbstractHyperproliferative diseases such as Chronic Lymphocytic Leukemia (CLL) and Systemic Lupus Erythematosus (SLE) are potentially related to some disturbance in the apoptosis pathway, specifically in B-1a cells (CD5+). Accumulation of B-1a cells in lymphoid organs, bone marrow or periphery is observed in some leukemia experimental murine models along aging. It is known that aging also increases the healthy B-1 cell population. However, it is not yet clear if it happens due to self-renewal of mature cells or proliferation of progenitor cells. Herein we demonstrated that the B-1 cell precursor population (B-1p) from bone...
Source: Experimental Hematology and Oncology - March 6, 2023 Category: Cancer & Oncology Source Type: research
Detection of myeloma cell-derived microvesicles: a tool to monitor multiple myeloma load
This study aimed to clarify the value of microvesicles in monitoring MM tumor load. Microvesicles in bone marrow and peripheral blood were isolated by differential ultracentrifugation and detected by flow cytometry. Western blotting was applied to assess myosin light chain phosphorylation levels. Flow cytometry to detect Ps+CD41a−, Ps+CD41a−CD138+, Ps+CD41a−BCMA+ microvesicles from bone marrow can be used to predict myeloma burden, furthermore, Ps+CD41a− microvesicles may as a potential index to MRD test. Mechanistically, the releasing of microvesicles from MM cell was regulated by Pim-2 Kinase via Phosphorylation ...
Source: Experimental Hematology and Oncology - March 6, 2023 Category: Cancer & Oncology Source Type: research
Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia
ConclusionsOur results demonstrated the synergistic effect of Chidamide with Cladribine on cell growth arrest, cell cycle arrest, and apoptosis in AML and primary cells with genetic defects by targeting HDAC2/c-Myc/RCC1 signaling in AML. Our data provide experimental evidence for the undergoing clinical trial (Clinical Trial ID: NCT05330364) of Chidamide plus Cladribine as a new potential regimen in AML. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - February 27, 2023 Category: Cancer & Oncology Source Type: research
Emerging roles of m6A RNA modification in cancer therapeutic resistance
AbstractMarvelous advancements have been made in cancer therapies to improve clinical outcomes over the years. However, therapeutic resistance has always been a major difficulty in cancer therapy, with extremely complicated mechanisms remain elusive. N6-methyladenosine (m6A) RNA modification, a hotspot in epigenetics, has gained growing attention as a potential determinant of therapeutic resistance. As the most prevalent RNA modification, m6A is involved in every links of RNA metabolism, including RNA splicing, nuclear export, translation and stability. Three kinds of regulators, “writer” (methyltransferase), “eraser...
Source: Experimental Hematology and Oncology - February 21, 2023 Category: Cancer & Oncology Source Type: research
Complement-related molecular classification and a gene signature for lung adenocarcinoma
ConclusionsIn summary, our study has established a new classification method and developed a prognostic signature for LUAD, while future studies are needed for further exploration of the underlying mechanism. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - February 21, 2023 Category: Cancer & Oncology Source Type: research
Emerging roles of m6A RNA modification in cancer therapeutic resistance
AbstractMarvelous advancements have been made in cancer therapies to improve clinical outcomes over the years. However, therapeutic resistance has always been a major difficulty in cancer therapy, with extremely complicated mechanisms remain elusive. N6-methyladenosine (m6A) RNA modification, a hotspot in epigenetics, has gained growing attention as a potential determinant of therapeutic resistance. As the most prevalent RNA modification, m6A is involved in every links of RNA metabolism, including RNA splicing, nuclear export, translation and stability. Three kinds of regulators, “writer” (methyltransferase), “eraser...
Source: Experimental Hematology and Oncology - February 21, 2023 Category: Cancer & Oncology Source Type: research
Complement-related molecular classification and a gene signature for lung adenocarcinoma
ConclusionsIn summary, our study has established a new classification method and developed a prognostic signature for LUAD, while future studies are needed for further exploration of the underlying mechanism. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - February 21, 2023 Category: Cancer & Oncology Source Type: research
Leukemogenic SHP2 mutations lead to erythropoietin independency of HCD-57 cells: a novel model for preclinical research of SHP2-mutant JMML
In conclusion, we established the novel cell lines HCD-57/SHP2-E76K and -D61Y that depended on signaling of mutant SHP2 for survival, thus resembling SHP2-mutant JMML. Our model is a valuable tool to investigate the pathogenic mechanisms of mutant SHP2 and targeted drugs for SHP2-mutant JMML. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - February 20, 2023 Category: Cancer & Oncology Source Type: research
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenstr öm’s macroglobulinemia
AbstractWaldenstr öm’s macroglobulinemia (WM) is an uncommon lymphoproliferative disorder, and the precise cellular landscape and the mechanisms of progression from IgM monoclonal gammopathy of undetermined significance (MGUS) to WM remain unclear. We performed single-cell RNA sequencing of CD19 + and CD19-CD3 8 + cells from healthy donors, IgM MGUS and WM patients. We found that samples from IgM MGUS and WM patients were composed of fewer early B-cell subsets and more T cells and NK cells than those from healthy controls. Compared with those of IgM MGUS patients, mature B cells of WM patients showed upregulatio...
Source: Experimental Hematology and Oncology - February 17, 2023 Category: Cancer & Oncology Source Type: research
Single-cell heterogeneity and dynamic evolution of Ph-like acute lymphoblastic leukemia patient with novel TPR-PDGFRB fusion gene
AbstractPhiladelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a refractory and recurrent subtype of B-cell ALL enriched with kinase-activating rearrangements. Incomplete understanding of the heterogeneity within the tumor cells presents a major challenge for the diagnosis and therapy of Ph-like ALL. Here, we exhibited a comprehensive cell atlas of one Ph-like ALL patient with a novelTPR-PDGFRB fusion gene at diagnosis and relapse by using single-cell RNA sequencing (scRNA-seq). Twelve heterogeneous B-cell clusters, four with strongMKI67 expression indicating highly proliferating B cells, were identifie...
Source: Experimental Hematology and Oncology - February 17, 2023 Category: Cancer & Oncology Source Type: research
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenstr öm’s macroglobulinemia
AbstractWaldenstr öm’s macroglobulinemia (WM) is an uncommon lymphoproliferative disorder, and the precise cellular landscape and the mechanisms of progression from IgM monoclonal gammopathy of undetermined significance (MGUS) to WM remain unclear. We performed single-cell RNA sequencing of CD19 + and CD19-CD3 8 + cells from healthy donors, IgM MGUS and WM patients. We found that samples from IgM MGUS and WM patients were composed of fewer early B-cell subsets and more T cells and NK cells than those from healthy controls. Compared with those of IgM MGUS patients, mature B cells of WM patients showed upregulatio...
Source: Experimental Hematology and Oncology - February 17, 2023 Category: Cancer & Oncology Source Type: research
Single-cell heterogeneity and dynamic evolution of Ph-like acute lymphoblastic leukemia patient with novel TPR-PDGFRB fusion gene
AbstractPhiladelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a refractory and recurrent subtype of B-cell ALL enriched with kinase-activating rearrangements. Incomplete understanding of the heterogeneity within the tumor cells presents a major challenge for the diagnosis and therapy of Ph-like ALL. Here, we exhibited a comprehensive cell atlas of one Ph-like ALL patient with a novelTPR-PDGFRB fusion gene at diagnosis and relapse by using single-cell RNA sequencing (scRNA-seq). Twelve heterogeneous B-cell clusters, four with strongMKI67 expression indicating highly proliferating B cells, were identifie...
Source: Experimental Hematology and Oncology - February 17, 2023 Category: Cancer & Oncology Source Type: research
Hypoxia-associated circPRDM4 promotes immune escape via HIF-1 α regulation of PD-L1 in hepatocellular carcinoma
ConclusionsThese findings illustrated that circPRDM4 promoted immune escape of HCC cells by facilitating the recruitment of HIF-1 α onto the promoter ofCD274 under hypoxia, thereby inhibiting CD8+ T cell infiltration in the tumor microenvironment. This work may provide a novel prognostic biomarker and therapeutic candidate for HCC immunotherapy. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - February 6, 2023 Category: Cancer & Oncology Source Type: research
